Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 199Rectal Neoplasms 106Colonic Neoplasms 78Stomach Neoplasms 64Pancreatic Neoplasms 56Neoplasm Metastasis 50Esophageal Neoplasms 34Neoplasms 25Lymphoma 24Leukemia 24Adenocarcinoma Of Esophagus 22Burkitt Lymphoma 20Precursor Cell Lymphoblastic Leukemia-Lymphoma 19Carcinoma, Hepatocellular 16Cholangiocarcinoma 15Adenocarcinoma 15Biliary Tract Neoplasms 12Gallbladder Neoplasms 9Bile Duct Neoplasms 8Lymphoma, Mantle-Cell 7Colorectal Cancer Metastatic 7Osteosarcoma 6Esophageal Squamous Cell Carcinoma 6Lymphoma, Non-Hodgkin 5Lymphoma, Large B-Cell, Diffuse 5Liver Neoplasms 5Dendritic Cell Sarcoma, Interdigitating 5Breast Neoplasms 5Sarcoma 4Peritoneal Neoplasms 4

Interventions

Oxaliplatin 2130-nm albumin-bound paclitaxel 2irinotecan sucrosofate 1folfirinox 1camrelizumab 1Surgical Procedures, Operative 1S 1 (combination) 1Leucovorin 1Gemcitabine 1Fluorouracil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Borderline Resectable Pancreatic Cancer × Leucovorin × Clear all
NCT06345300 2024-04-03

NALIRIFOX in Combination With Camrelizumab for BRPC: a Prospective, Exploratory Study

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Unknown
40 enrolled
Gastrointestinal

Borderline Resectable Pancreatic Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡